UroGen Submits NDA for Investigational Bladder Cancer Treatment

UroGen Pharma has submitted a New Drug Application (NDA) for UGN-103, an investigational treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).